Diagnostic Utility of Epithelial Membrane Antigen in Distinguishing between Reactive Mesothelial and Metastatic Adenocarcinoma Cells in Serous Cavity Fluid

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Gastroenterology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Student Research committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The cytological diagnoses of serous effusions are usually made by routine cytomorphology with certainty. However, overlapping cases sometimes exist between reactive mesothelial and adenocarcinoma cells. We tried to evaluate the diagnostic utility of epithelial membrane antigen (EMA) monoclonal antibody in distinguishing between reactive mesothelial cells and adenocarcinoma in serous effusions.Methods: Paraffin blocks and hematoxylin and eosin stained slides of peritoneal and pleural fluid cell blocks were retrieved from cytology archive of Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran, during 2006-2010. From among 1025 slides which were screened to ascertain their appropriate diagnoses, 90 paraffin embedded cell blocks, 30 cases for adenocarcinoma and 60 cases for reactive mesothelial groups were selected for immunocytochemistry staining. Cellular reactivity, intensity, and pattern of staining for EMA were evaluated by anti-human EMA "clone E29". Statistical analyses and tests of significance were performed using SPSS.Findings: Mean age of the patients in the reactive mesothelial and adenocarcinoma groups were 50.28 and 55.16 years, respectively. The malignant group included 22 (73.33%) female and 8 (26.66%) male cases. In the reactive group however, 16 (26.66%) females and 44 (73.33%) males were studied. The mean numbers of immunoreactive cells for EMA in adenocarcinomatous and reactive mesothelial cells were 97.5 ± 7.62 and 21.6 ± 30.43, respectively (P = 0.001). In addition, 30 (100%) and 8 (13.33%) severe immunoreactive cases were observed in the metastatic adenocarcinoma and reactive mesothelial groups, respectively (P = 0.001). Conclusion: Immunocytochemical staining for EMA is a useful diagnostic tool for distinguishing effusions containing malignant cells from those with benign cells. We particularly suggest the precise evaluation of pattern and intensity of immunoreactive cells for EMA.

Keywords

References

  1. Hong EK. The cytopathology of body cavity fluid. Korean J Cytopathol 2008; 19(2): 72-85.
  2. Naylor B. Pleural, peritoneal and pericardial effusions. In: Bibbo M, Wilbur D, editors. Comprehensive Cytopathology. 3rd ed. Philadelphia: Saunders; 2008.
  3. Sayed DM, el-Attar MM, Hussein AA. Evaluation of flow cytometric immunophenotyping and DNA analysis for detection of malignant cells in serosal cavity fluids. Diagn Cytopathol 2009; 37(7): 498-504.
  4. Rahmani A, Dehghani MZ, Afshar NM, Heidarian H, Tahririan R. HBME-1 immunostaining in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid. Indian J Pathol Microbiol 2011; 54(3): 460-3.
  5. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol 2006; 13(4): 174-84.
  6. Murugan P, Siddaraju N, Habeebullah S, Basu D. Immunohistochemical distinction between mesothelial and adenocarcinoma cells in serous effusions: a combination panel-based approach with a brief review of the literature. Indian J Pathol Microbiol 2009; 52(2): 175-81.
  7. Terada T. Immunohistochemical profile of normal mesothelium and histiocytic/methothelial hyperplasia: a case report. Int J Clin Exp Pathol 2011; 4(6): 631-6.
  8. Pierson DM, Jones D, Muzzafar T, Kersh MJ, Challagundla P, Medeiros LJ, et al. Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens. Cytometry B Clin Cytom 2008; 74(6): 341-8.
  9. Shidham VB, Falzon M. Serous effusions. In: Gray W, Kocjan G, editors. Diagnostic Cytopathology. 3rd ed. Churchill Livingstone Elsevier: Philadelphia (US); 2010. p. 115–78.
  10. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, P53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003; 43(3): 231-8.
  11. Ueda J, Iwata T, Ono M, Takahashi M. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Diagn Cytopathol 2006; 34(1): 6-10.
  12. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11(1): 8-17.
  13. Rosai J. Special techniques in surgical pathology. In: Rosai J. Rosai and Ackerman`s surgical pathology. 10th ed. New York: Mosby; 2011. p. 45-65.
  14. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol 2011; 39(6): 395-401.
  15. Alexa A, Baderca F, Lighezan R, Zahoi DE, Izvernariu D. The diagnostic value of EMA expression in the renal parenchyma tumors. Rom J Morphol Embryol 2011; 52(3 Suppl): 1019-25.
  16. Ensani F, Nematizadeh F, Irvanlou G. Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions. Pol J Pathol 2011; 62(2): 95-100.
  17. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006; 49(6): 561-8.
  18. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994; 11(3): 237-45.
  19. Su XY, Li GD, Liu WP, Xie B, Jiang YH. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Diagn Cytopathol 2011; 39(12): 900-8.
  20. Saad RS, Cho P, Liu YL, Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005; 32(3): 156-9.
  21. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer 2001; 93(5): 293-308.
  22. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005; 32(3): 151-5.
  23. Pinkus GS, Kurtin PJ. Epithelial membrane antigen--a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol 1985; 16(9): 929-40.
Journal of Isfahan Medical School
Volume 29, Issue 170 - Serial Number 170
November and December 2012
Pages 2715-2721

Files

History

  • Receive Date: 27 December 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics